Keytruda® (pembrolizumab) – New indication
November 1, 2023 - Merck announced the FDA approval of Keytruda (pembrolizumab), in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (BTC).
Download PDF
